Research ArticleCanadian Recommendations and Systematic Literature Reviews for the Assessment and Monitoring of Systemic Lupus Erythematosus Using GRADE
Open Access

Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis

Sara Hussein, Manon Suitner, Sarah Béland-Bonenfant, Alexandra Baril-Dionne, Ben Vandermeer, Nancy Santesso, Stephanie Keeling, Janet E. Pope, Aurore Fifi-Mah and Josiane Bourré-Tessier
The Journal of Rheumatology October 2018, 45 (10) 1462-1476; DOI: https://doi.org/10.3899/jrheum.170837

Abstract

Objective. Nontraumatic osteonecrosis (ON) is a well-recognized complication causing disability and affecting quality of life in patients with systemic lupus erythematosus (SLE). The aim of this study was to identify the risk factors for ON, and to identify the minimal investigation(s) needed to optimally monitor the risk of ON in patients with SLE.

Methods. A systematic review was conducted using MEDLINE and EMBASE. These databases were searched up to January 2016 using the Medical Subject Heading (MeSH) terms “Osteonecrosis,” “Systemic lupus erythematosus,” and synonymous text words. Randomized controlled trials, case control, cohort, and cross-sectional studies were included. Risk factors for ON in patients with SLE were compiled. The quality of each study was assessed using the Newcastle-Ottawa scale for nonrandomized studies. The quality of evidence of each risk factor was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation method.

Results. Of the 545 references yielded, 50 met inclusion criteria. Corticosteroid (CS) use may be strongly associated with ON in patients with SLE. Other clinical variables were moderately associated, including hypertension, serositis, renal disease, vasculitis, arthritis, and central nervous system disease. However, the evidence was low to very low in quality.

Conclusion. Based on the best evidence available, CS use may be strongly associated with ON in patients with SLE. Results of this review were considered in the development of recommendations for the diagnosis and monitoring of patients with SLE in Canada and will guide clinicians in their assessment of these patients.

Key Indexing Terms:

Osteonecrosis (ON), also known as avascular necrosis of the bone, is a well-recognized complication in systemic lupus erythematosus (SLE). The clinical presentation of ON is variable; it may be clinically silent or present with gradual-onset pain that can progress to severe pain, bone collapse, and joint damage, causing restriction of the range of motion and eventually requiring total joint arthroplasty. The prevalence of ON in patients with SLE ranges between 10% and 15%, but can reach as high as 44% when asymptomatic lesions are included1,2. Multifocal ON is frequent in patients with SLE; bilateral hip ON has been reported to occur in up to 90% of patients with SLE who have ON2.

Previous studies have demonstrated that symptomatic ON frequently causes disability and considerably affects quality of life3, as measured by the Health Assessment Questionnaire and/or the 20-item Short Form Health Survey (SF-20)4,5. As shown by the presence of the item “avascular necrosis” in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index for SLE, ON is a well-recognized feature of the accumulated damage in SLE6.

The pathophysiology of ON is not completely understood. It is likely the result of the combined effects of genetic predisposition, metabolic factors, and other factors affecting blood supply7. Ultimately, ON is characterized by bone death, which may be due to traumatic or atraumatic factors decreasing blood supply or causing osteotoxicity. Many theories regarding the mechanisms leading to blood interruption have been proposed and include increased bone marrow pressure and intravascular occlusion of subchondral vessels by coagulation, fat emboli, thrombi, or abnormally shaped red blood cells. Moreover, direct osteotoxicity by alcohol and drugs can lead to bone cell death8. Although the use of corticosteroids (CS) has been recognized as a major risk factor for the development of ON, ON occurs more frequently in patients with SLE than in any other illness requiring administration of systemic CS9. This suggests that the use of CS may not be the only risk factor associated with the development of ON in patients with SLE. As part of the development of Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)–based Canadian recommendations in SLE, we conducted this systematic literature review to determine the different risk factors for ON in patients with SLE. The specific question addressed was, “what are the minimum investigation(s) necessary to optimally monitor the risk of ON in SLE patients?” To answer this question, the identification of all the risk factors associated with ON in SLE was necessary, and that was the goal of our present study.

MATERIALS AND METHODS

Search strategy

A comprehensive and systematic search was performed using MEDLINE and EMBASE. Each database was searched from its inception to January 2016 in both French and English. A broad combination of Medical Subject Heading (MeSH) terms included “Systemic lupus erythematosus,” “Osteonecrosis,” “Aseptic necrosis,” “Avascular necrosis,” “Femur head necrosis,” and synonymous text words. Additional articles were retrieved by hand-searching relevant references and guidelines, especially European League Against Rheumatism recommendations10,11 and ACR Appropriateness Criteria12. Ethics board approval for a systematic review and metaanalysis was not required, in accordance with the policy of our institution (Centre Hospitalier de l’Université de Montréal). The end date for the search represents when this review was completed for the results to be used for the GRADE-based recommendations for assessment and monitoring of SLE in Canada; therefore, the search was not further updated, to ensure consistency of data.

Study selection

Two reviewers (SH and MS) screened all articles based on titles and abstracts and selected potentially eligible studies. Full-text articles of all relevant studies were retrieved and assessed for inclusion, based on specific eligibility criteria: (1) randomized controlled trials (RCT), case control, cohort, or cross-sectional studies; (2) patients diagnosed with SLE (according to authors of the articles); (3) symptomatic and/or asymptomatic ON (any joint could be affected); (4) ON confirmed by 1 or more of the following methods: conventional radiography, bone scan, magnetic resonance imaging (MRI), tomograms, or histology; and (5) reporting of at least 1 risk factor for ON. Exclusion criteria included any of the following: (1) case reports, letters, and review articles; (2) non-human studies; and (3) publication in languages other than French or English.

Data extraction

A standard data extraction form was used to collect the relevant information from the included studies. Extracted data included year of publication, country, study design, source of funding, sample size, SLE definition, and ON definition. The risk factors evaluated were grouped into 4 categories: (1) those related to CS [history of CS use, current CS use (yes/no), mean daily dose of CS, highest dose of CS (mg/day and g/month), total cumulative CS dose, Cushingoid appearance]; (2) those related to clinical manifestations [disease activity, arthritis, neuropsychiatric SLE, Raynaud phenomenon (RP), vasculitis, serositis, gastrointestinal (GI) involvement, hypertension (HTN), oral ulcers, renal disease, alopecia]; (3) those related to laboratory results [lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) IgM and IgG, anti-β2-glycoprotein] I antibody; and (4) those related to treatment other than CS (antimalarial, immunosuppressive agents).

Quality assessment

Because no RCT were identified, the quality of each study was graded according to the Newcastle-Ottawa scale for nonrandomized studies (NOS)13, a tool developed to assess the quality of that type of study. A maximum of 9 stars could be attributed to each study, with a higher number of stars indicating a higher quality. In addition, the quality of the evidence per risk factor was evaluated according to GRADE approach14, which encompasses 8 major domains: risk of bias, directness of evidence, inconsistency, imprecision, publication bias, large effect, dose response, and opposing residual confounding.

Statistical analysis

For each included study and for each relevant outcome, we extracted or computed the necessary information. For binary outcomes (e.g., renal disease), we obtained OR with corresponding standard errors. When OR were not given directly, they were computed from raw data or other given information (e.g., risk ratios). For continuous outcomes (e.g., highest dose of CS), we obtained mean difference with standard error. Standard errors of the mean difference (when not given directly) were computed from other information (e.g., SD, CI, and p values). Results were then pooled using the DerSimonian-Laird random effects method; OR were pooled on the log scale15. For study level and pooled estimates, 95% CI were reported. Statistical heterogeneity was quantified using the I2 statistic16.

RESULTS

Literature search

After removing duplicate results, 370 references were identified. Of these studies, 304 records were excluded after initial review of titles and abstracts. After evaluation of the full-length paper of the remaining 66 articles, 50 studies were included in the final analysis (Figure 1). The majority of full-text articles were excluded because they did not include a comparator group (patients with SLE without ON) or because of lack of extractable data.

Figure 1.
Figure 1.

Flow diagram of the literature search process, including reasons for exclusions. ON: osteonecrosis; SLE: systemic lupus erythematosus.

Study characteristics

The details of the study characteristics are displayed in Supplementary Table 1, available with the online version of this article. No RCT was identified. Almost all included studies were the case-control type (46 of 50 studies). The NOS scores varied between 3 and 8, with a mean score ± SD of 5.72 ± 1.06 and a median score of 6. One article had a score of 8, 10 articles had a score of 7, 18 articles had a score of 6, and 18 articles had a score of 5 or lower. The quality of the body of evidence for each risk factor was assessed as low to very low because of risk of bias, inconsistency, and imprecision for most risk factors (Table 1).

View this table:
Table 1.

Summary of the evidence quality grading using GRADE.

Risk factors related to CS

Several approaches were taken to evaluate the risk associated with CS (Figure 2). Three studies examined current use (yes/no) for patients with SLE17,18,19. One found a statistically significant higher risk of ON in patients using CS compared to those without CS use, whereas the other 2 studies did not. Although not statistically significant, a trend toward increased risk of ON was observed when the 3 studies were combined. One study looked at the history of CS use (yes/no) and did not find an association with ON20. Combining the results of 23 studies3,17,18,21–40, total cumulative dose of CS was higher in patients with SLE who had ON than in patients with SLE without ON (mean difference 3.71 g, 95% CI 0.79–6.64). The average daily dose3,18,29,30,32,34,35,37,38,40–46 and the highest daily dose1–3,17,18,22,24–28,34,38–40,42,46–51 were also higher in patients who presented with ON (mean difference 3.19 mg/day, 95% CI 1.18–5.21, and mean difference 6.41 mg/day, 95% CI 2.94–9.88, respectively). The highest cumulative CS dose received in 1 month was, however, not statistically different between patients with SLE with or without ON30,31,32,35. The use of pulse therapy has been studied in 17 articles2,3,20,28,30,32,35,41,43,45,48,52–57 and was associated with ON (OR 1.79, 95% CI 1.31–2.46). Cushingoid appearance was also a risk factor associated with ON (OR 3.66, 95% CI 2.20–6.10)1,3,17,27,30,32,40,46,52,54,58.

Figure 2A–B.
Figure 2A–B.

Forest plots for risk factors associated with corticosteroid use: A. CS use; B. Total cumulative CS dose (g). CS: corticosteroids.

Risk factors related to clinical manifestations

Significant risk factors associated with ON (Figure 3) were arthritis (OR 1.50, 95% CI 1.04–2.16)3,17,20,22,25,26,35,37,39,40,42,46,54,59,60, neuropsychiatric manifestations of SLE (OR 2.03, 95% CI 1.52–2.72)17,20,21,22,25,26,30,32,35–40,42,46,47,48,52,53,55,57,59–62, RP (OR 1.28, 95% CI 1.06–1.54)3,17,20–22,24–27,30,32,35,36,37, 39–41,44,46–48,52,57,58,60, vasculitis (OR 2.13, 95% CI 1.48–3.07)1,17,22,25,27,30,32,35,36,40,46,52,54,58,61, and HTN (OR 1.76, 95% CI 1.49–2.08)3,19,20,22,30,32,35,37,38,40,42,45,48,53,61. There was also a higher risk of ON in patients with SLE presenting with serositis, including pericarditis and/or pleuritis (OR 1.68, 95% CI 1.24–2.26)22,25,30,32,35,37, 40,43,54,59–61. Renal disease, defined as proteinuria of > 0.5 g/day and/or active urinary sediment and/or creatinine > 1.4 mg/dl (123.2 µmol/l) and/or biopsy-proven lupus nephritis, was also a risk factor for ON (OR 1.70, 95% CI 1.32–2.19)3,17,19,20,22,25,26,30,32,35,36,37–40,43,46–48,53,54,57,59–61). One study27 evaluated disease activity as a risk factor for ON in patients with SLE and found that a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 8 in the previous year statistically increases the risk of ON (OR 6.78, 95% CI 1.05–43.66). Alopecia25,30,32,35,37,40,43,44,60 and oral ulcers22,25,26,30,32,35,40,43,46,59,60 did not show a significant association with ON. Only 1 study evaluated GI involvement as a risk factor for ON in patients with SLE61, and it did not find a statistically significant association.

Figure 2C–E.
Figure 2C–E.

Forest plots for risk factors associated with corticosteroid use: C. Average daily CS dose (mg/day); D. Highest CS dose (mg/day); E. Highest CS dose (g/month). CS: corticosteroids.

Figure 2F–G.
Figure 2F–G.

Forest plots for risk factors associated with corticosteroid use: F. Corticosteroid pulse; G. Cushingoid appearance.

Figure 3A–B.
Figure 3A–B.

Forest plots for clinical manifestations of SLE: A. Arthritis; B. Neuropsychiatric SLE. SLE: systemic lupus erythematosus.

Risk factors related to laboratory results

Overall, studies that investigated the association between aCL and ON did not find a significant association (Figure 4)3,17,20,26,57. In studies that looked at aCL subtypes, aCL IgM were more often positive in patients with SLE who had ON compared to patients without (OR 2.29, 95% CI 1.31–3.98)1,22,27,32,33,35,36,59; however, aCL IgG1,22,27,30,32,33,35,36,38,59 and LAC22,26,27,30,32,33,35,42,48,57,59 were not associated with ON. The 2 studies that evaluated the association between anti-B2-glycoprotein I antibody and ON found no association30,63. Interestingly, 1 study found an association between vitamin D deficiency and ON19.

Figure 3C–D.
Figure 3C–D.

Forest plots for clinical manifestations of SLE: C. Raynaud phenomenon; D. Vasculitis. SLE: systemic lupus erythematosus.

Figure 3E–H.
Figure 3E–H.

Forest plots for clinical manifestations of SLE: E. Serositis; F. Gastrointestinal involvement; G. Hypertension; H. Oral ulcers. SLE: systemic lupus erythematosus.

Figure 3I–K.
Figure 3I–K.

Forest plots for clinical manifestations of SLE: I. Renal disease; J. Alopecia; K. SLEDAI > 8. SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index.

Figure 4.
Figure 4.

Forest plots for risk factors associated with laboratory results: A. Anticardiolipin antibodies IgM; B. Anticardiolipin antibodies IgG; C. Lupus anticoagulant.

Risk factors related to treatment other than CS

The use of antimalarials3,17,20,22,26,27,38,42,53,57,59,61,62,64 showed no effect on the risk of ON (Figure 5). The use of at least 1 immunosuppressive agent (including methotrexate, azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil) was associated with an increased risk of ON (OR 1.87, 95% CI 1.17–2.98)3,17,27,35,48,52,53,54,57,61. When studied independently, cyclophosphamide was the only immunosuppressive agent associated with the development of ON (OR 2.98, 95% CI 1.33–6.68)22,26,30,32,38,42,59. Azathioprine22,23,26,30,32,38,42,59, methotrexate26,53,59, and mycophenolate mofetil22,26,30,38 were not associated with a higher risk of ON.

Figure 5A.
Figure 5A.

Forest plots for risk factors associated with medication other than CS: A. Antimalarials. CS: corticosteroids.

Figure 5B.
Figure 5B.

Forest plots for risk factors associated with medication other than CS: B. Immunosuppressive agents. CS: corticosteroids.

DISCUSSION

The objective of our study was to determine the risk factors associated with ON, an important complication affecting patients with SLE. Our systematic review of the literature revealed that studies were heterogeneous in terms of design and quality. Nevertheless, some important points emerged.

CS are a risk factor that may be associated with ON. The average daily dose of CS, highest dose of CS, total cumulative CS dose, pulse therapy, and Cushingoid appearance were all associated with ON. However, the quality of this evidence was low to very low because of the high risk of bias and often inconsistency across studies, and therefore strong conclusions cannot be made. Although 2 of the 3 studies that investigated the current use of CS and the study that examined the history of CS use did not show a statistically significant association with ON, a clear tendency in favor of an association was observed.

This is in agreement with the observation that ON is rarely observed in patients with SLE who did not receive CS17. Also, empirical evidence suggests that ON is closely associated with the use of high-dose CS early in the course of SLE, especially in patients who develop Cushingoid appearance1,17,32,40,54,65. However, 1 study of 144 patients followed by periodic MRI (hips and knees) for a minimum of 10 years found no new lesion development in patients receiving a low or medium CS dose (< 30 mg/day of prednisone)34.

Although the effect of CS on ON seems to be clearly established, the pathophysiology is not fully understood. It has been hypothesized that chronic CS use promotes intraosseous adipocyte hypertrophy and fat conversion of red marrow, leading to increased bone marrow pressure, which compromises intraosseous perfusion8. Another postulated mechanism is that CS alter lipid metabolism, leading to fat microemboli in subchondral vessels8.

The higher prevalence of ON in patients with SLE compared to other diseases requiring CS therapy suggests that additional SLE-specific risk factors may be involved9. Indeed, our systematic review identified additional possible risk factors for ON in patients with SLE; however, not all data regarding these risk factors were concordant.

Although antimalarials may have antithrombotic66 and lipid-lowering properties67, our review showed that using antimalarials may have little to no effect on the risk of ON in patients with SLE.

ON has been identified in patients with primary antiphospholipid syndrome without previous CS therapy, suggesting a role for antiphospholipid antibodies (aPL) in the pathophysiology of ON68. Indeed, it is reasonable to think that these antibodies may induce a hypercoagulable state that could cause vessel thrombosis and lead to bone ischemia and necrosis. The various studies on the risk of ON associated with aPL in SLE showed conflicting data, and the pooled result showed that there may only be an association with aCL of the IgM subtype, but this is uncertain. This observation is certainly difficult to explain, but is consistent with another metaanalysis published on this subject that found the same result69. Another one70 did not find a strong correlation between aPL and the occurrence of ON. Thus, the true character of the association between aPL and ON in SLE is not clear and seems to be, at best, weak.

It could be postulated that immunosuppressive agents could lead to ON by a direct cytotoxic effect on osteoblasts and osteoclasts. In fact, some authors found that immunosuppressive therapy is a risk factor for ON17,22,30,32,42,57. Conversely, these agents could be surrogates for disease activity, which could be a risk for ON. Also, their use likely clusters with CS but their use could also be steroid-sparing. In most of these studies, immunosuppressive therapy was not studied as an independent risk factor. However, 1 study found that cytotoxic drug use remained a significant risk factor for the occurrence of ON, even after adjusting for the use of CS and other treatments42. In our study, no difference was observed between ON cases and controls regarding disease activity. Similarly, another article found that cytotoxic drugs remain a significant risk factor for ON in multivariate analysis (OR 2.7, 95% CI 1.02–8.8; p = 0.046)17.

Our review provides a comprehensive picture of the risk factors of ON in patients with SLE. It was conducted as part of the development of Canadian clinical practice recommendations for the diagnosis and monitoring of patients with SLE, which are the first, to our knowledge, to use the GRADE methodology for SLE and are endorsed by different SLE associations across Canada. The aim of our review was to identify subgroups of patients with SLE at risk of ON, and to optimally monitor them for this debilitating complication. The strength of this metaanalysis is that we used a systematic approach and established a quality of evidence for each risk factor with the GRADE approach. However, some limitations must be identified. First, only a few included studies controlled for confounders and provided adjusted results. This may help explain the notable heterogeneity for some outcomes. We reported adjusted results whenever possible, because many risk factors for ON may be codependent. Second, all studies included in this review had an observational design, and therefore causality cannot be inferred. Also, the different diagnostic methods of ON (with varying sensitivity) used in the included studies are a source of heterogeneity. Finally, although some studies were graded as good quality according to the NOS scale, the quality of evidence for the risk factors was low to very low based on GRADE. This limits our ability to draw strong conclusions concerning some risk factors.

Based on the published literature, CS may be a strong risk factor associated with ON in patients with SLE. Other risk factors, such as arthritis, neuropsychiatric manifestations of SLE, vasculitis, hypertension, serositis, and renal disease may be moderately associated with ON, and a SLEDAI score > 8 may be strongly associated with ON, but this is still uncertain due to the very low quality of evidence. Results of this review may be considered by clinicians in their assessment of the risk of ON in patients with SLE. A careful medical history should be obtained, including information about CS use. Physicians should maintain a high index of suspicion for ON in patients with SLE, especially in the presence of known risk factor such as the use of CS. Patients should be educated on the presenting symptoms of ON (progressive or sudden deep joint pain worse with movements). We suggest adopting a preventive strategy with a judicious use of CS.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

Acknowledgment

We thank all the members of the Canadian SLE working group. We also thank Isabelle Théotol for her assistance in the literature search.

Footnotes

  • Full Release Article. For details see Reprints and Permissions at jrheum.org

  • Accepted for publication February 16, 2018.

Free online via JRheum Full Release option

REFERENCES

  1. 1.↵
    1. Mont MA,
    2. Glueck CJ,
    3. Pacheco IH,
    4. Wang P,
    5. Hungerford DS,
    6. Petri M
    . Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997;24:654–62.
    OpenUrlPubMed
  2. 2.↵
    1. Oinuma K,
    2. Harada Y,
    3. Nawata Y,
    4. Takabayashi K,
    5. Abe I,
    6. Kamikawa K,
    7. et al.
    Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001;60:1145–8.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Prasad R,
    2. Ibanez D,
    3. Gladman D,
    4. Urowitz M
    . The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus 2007;16:157–62.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Gladman DD,
    2. Chaudhry-Ahluwalia V,
    3. Ibañez D,
    4. Bogoch E,
    5. Urowitz MB
    . Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001;28:2226–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ghaleb RM,
    2. Omar GM,
    3. Ibrahim MA
    . Avascular necrosis of bone in H. Oral ulcers. SLE: systemic lupus erythematosus. systemic lupus erythematosus. Egypt Rheumatologist 2011;33:27–33.
    OpenUrl
  6. 6.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.
    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mont MA,
    2. Hungerford DS
    . Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995;77:459–74.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Shah KN,
    2. Racine J,
    3. Jones LC,
    4. Aaron RK
    . Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med 2015;8:201–9.
    OpenUrl
  9. 9.↵
    1. Fukushima W,
    2. Fujioka M,
    3. Kubo T,
    4. Tamakoshi A,
    5. Nagai M,
    6. Hirota Y
    . Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 2010;468:2715–24.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Van der Goes MC,
    2. Jacobs JW,
    3. Boers M,
    4. Andrews T,
    5. Blom-Bakkers MA,
    6. Buttgereit F,
    7. et al.
    Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913–9.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Duru N,
    2. van der Goes MC,
    3. Jacobs JW,
    4. Andrews T,
    5. Boers M,
    6. Buttgereit F,
    7. et al.
    EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905–13.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Murphey MD,
    2. Roberts CC,
    3. Bencardino JT,
    4. Appel M,
    5. Arnold E,
    6. Chang EY,
    7. et al;
    8. Expert Panel on Musculoskeletal Imaging
    . ACR appropriateness criteria osteonecrosis of the hip. J Am Coll Radiol 2016;13:147–55.
    OpenUrl
  13. 13.↵
    1. Wells G,
    2. Shea B,
    3. O’Connell D,
    4. Peterson J,
    5. Welch V,
    6. Losos M
    . The Newcastle-Ottawa Scale [NOS] for assessing the quality of nonrandomised studies in meta-analyses. [Internet. Accessed May 14, 2018.] Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  14. 14.↵
    1. Higgins JPT,
    2. Green S
    . Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. [Internet. Accessed May 14, 2018.] Available from: handbook-5-1.cochrane.org
  15. 15.↵
    1. DerSimonian R,
    2. Laird N
    . Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Higgins JP,
    2. Thompson SG
    . Quantifying heterogeneity in a meta-analysis. Stat Med 2002 15;21:1539–58.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Gladman DD,
    2. Urowitz MB,
    3. Chaudhry-Ahluwalia V,
    4. Hallet DC,
    5. Cook RJ
    . Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:761–5.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gurion R,
    2. Yang H,
    3. Li H
    . Risk factors for the development of avascular necrosis in pediatric systemic lupus erythematosus patients [abstract]. Arthritis Rheum 2013;65:S536–S7.
    OpenUrl
  19. 19.↵
    1. Gurion R,
    2. Tangpricha V,
    3. Yow E,
    4. Schanberg LE,
    5. McComsey GA,
    6. Robinson AB;
    7. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators
    . Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J 2015;13:13.
    OpenUrl
  20. 20.↵
    1. Cozen L,
    2. Wallace DJ
    . Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop 1998;27:352–4.
    OpenUrlPubMed
  21. 21.↵
    1. Abeles M,
    2. Urman JD,
    3. Rothfield NF
    . Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978;138:750–4.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Al Saleh J,
    2. El Sayed M,
    3. Salah N,
    4. Harb D,
    5. Khan N,
    6. Mohammed N
    . Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Egypt J Immunol 2010;17:29–40.
    OpenUrlPubMed
  23. 23.↵
    1. Bergstein JM,
    2. Wiens C,
    3. Fish AJ,
    4. Vernier RL,
    5. Michael A
    . Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr 1974;85:31–5.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Castro TC,
    2. Lederman H,
    3. Terreri MT,
    4. Caldana WI,
    5. Kaste SC,
    6. Hilário MO
    . The use of joint-specific and whole-body MRI in osteonecrosis: a study in patients with juvenile systemic lupus erythematosus. Br J Radiol 2011;84:621–8.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Dimant J,
    2. Ginzler EM,
    3. Diamond HS,
    4. Schlesinger M,
    5. Marino CT,
    6. Weiner M,
    7. et al.
    Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 1978;5:136–41.
    OpenUrlPubMed
  26. 26.↵
    1. Faezi ST,
    2. Hoseinian AS,
    3. Paragomi P,
    4. Akbarian M,
    5. Esfahanian F,
    6. Gharibdoost F,
    7. et al.
    Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study. Modern Rheumatology 2015;25:590–4.
    OpenUrl
  27. 27.↵
    1. Fialho SC,
    2. Bonfá E,
    3. Vitule LF,
    4. D’Amico E,
    5. Caparbo V,
    6. Gualandro S,
    7. et al.
    Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 2007;16:239–44.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Hagiwara S,
    2. Nakamura J,
    3. Watanabe A,
    4. Kishida S,
    5. Ohtori S,
    6. Omae T,
    7. et al.
    Corticosteroids and low bone mineral density affect hip cartilage in systemic lupus erythematosus patients: Quantitative T2 mapping. J Magn Reson Imaging 2015;42:1524–31.
    OpenUrl
  29. 29.↵
    1. Houssiau FA,
    2. N’Zeusseu Toukap A,
    3. Depresseux G,
    4. Maldague BE,
    5. Malghem J,
    6. Devogelaer JP,
    7. et al.
    Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 1998;37:448–53.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Lee J,
    2. Kwok SK,
    3. Jung SM,
    4. Min HK,
    5. Nam HC,
    6. Seo JH,
    7. et al.
    Osteonecrosis of the hip in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus 2014;23:39–45.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Migliaresi S,
    2. Picillo U,
    3. Ambrosone L,
    4. Di Palma G,
    5. Mallozzi M,
    6. Tesone ER,
    7. et al.
    Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 1994;3:37–41.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Mok CC,
    2. Lau CS,
    3. Wong RW
    . Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998;37:895–900.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Mok MY,
    2. Farewell VT,
    3. Isenberg DA
    . Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000;59:462–7.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Nakamura J,
    2. Ohtori S,
    3. Sakamoto M,
    4. Chuma A,
    5. Abe I,
    6. Shimizu K
    . Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence. Clin Exp Rheumatol 2010;28:13–8.
    OpenUrlPubMed
  35. 35.↵
    1. Sayarlioglu M,
    2. Yuzbasioglu N,
    3. Inanc M,
    4. Kamali S,
    5. Cefle A,
    6. Karaman O,
    7. et al.
    Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 2012;32:177–82.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Sheikh JS,
    2. Retzinger GS,
    3. Hess EV
    . Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis. Lupus 1998;7:42–8.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Smith FE,
    2. Sweet DE,
    3. Brunner CM,
    4. Davis JS 4th
    . Avascular necrosis in SLE. An apparent predilection for young patients. Ann Rheum Dis 1976;35:227–32.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Uea-areewongsa P,
    2. Chaiamnuay S,
    3. Narongroeknawin P,
    4. Asavatanabodee P
    . Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol 2009;15:345–9.
    OpenUrlPubMed
  39. 39.↵
    1. Watanabe T,
    2. Tsuchida T,
    3. Kanda N,
    4. Tamaki K
    . Avascular necrosis of bone in systemic lupus erythematosus. The predictive role of precipitating autoantibodies. Scand J Rheumatol 1997;26:184–7.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Zizic TM,
    2. Marcoux C,
    3. Hungerford DS,
    4. Dansereau JV,
    5. Stevens MB
    . Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985;79:596–604.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Aranow C,
    2. Zelicof S,
    3. Leslie D,
    4. Solomon S,
    5. Barland P,
    6. Norman A,
    7. et al.
    Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 1997;24:2318–22.
    OpenUrlPubMed
  42. 42.↵
    1. Calvo-Alén J,
    2. McGwin G,
    3. Toloza S,
    4. Fernández M,
    5. Roseman JM,
    6. Bastian HM,
    7. et al;
    8. LUMINA Study Group
    . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 2006;65:785–90.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Kuroda T,
    2. Tanabe N,
    3. Wakamatsu A,
    4. Takai C,
    5. Sato H,
    6. Nakatsue T,
    7. et al.
    High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol 2015;34:2071–7.
    OpenUrl
  44. 44.↵
    1. Ono K,
    2. Tohjima T,
    3. Komazawa T
    . Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res 1992;277:89–97.
    OpenUrlPubMed
  45. 45.↵
    1. Sekiya F,
    2. Yamaji K,
    3. Yang K,
    4. Tsuda H,
    5. Takasaki Y
    . Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatol Int 2010;30:1587–93.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Weiner ES,
    2. Abeles M
    . Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989;16:604–8.
    OpenUrlPubMed
  47. 47.↵
    1. Klippel JH,
    2. Gerber LH,
    3. Pollak L,
    4. Decker JL
    . Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecrosis. Am J Med 1979;67:83–7.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Nagasawa K,
    2. Ishii Y,
    3. Mayumi T,
    4. Tada Y,
    5. Ueda A,
    6. Yamauchi Y,
    7. et al.
    Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 1989;48:672–6.
    OpenUrlAbstract/FREE Full Text
  49. 49.
    1. Nakamura J,
    2. Saisu T,
    3. Yamashita K,
    4. Suzuki C,
    5. Kamegaya M,
    6. Takahashi K
    . Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 2010;62:609–15.
    OpenUrlPubMed
  50. 50.
    1. Shigemura T,
    2. Nakamura J,
    3. Kishida S,
    4. Harada Y,
    5. Ohtori S,
    6. Kamikawa K,
    7. et al.
    Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatol 2011;50:2023–8.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Shigemura T,
    2. Nakamura J,
    3. Harada Y
    . Incidence of steroid-associated osteonecrosis of the talus: a prospective MRI study. Eur Orthop Traumatol 2013;4:237–40.
    OpenUrl
  52. 52.↵
    1. Hamijoyo L,
    2. Llamado LJ,
    3. Navarra SV
    . Risk factors for avascular necrosis among Filipino patients with systemic lupus erythematosus. Int J Rheum Dis 2008;2:141–7.
    OpenUrl
  53. 53.↵
    1. Joo YB,
    2. Sung YK,
    3. Shim JS,
    4. Kim JH,
    5. Lee EK,
    6. Lee HS,
    7. et al.
    Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study. Rheumatol Int 2015;35:879–86.
    OpenUrl
  54. 54.↵
    1. Massardo L,
    2. Jacobelli S,
    3. Leissner M,
    4. González M,
    5. Villarroel L,
    6. Rivero S
    . High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1992;1:401–5.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Nagasawa K,
    2. Tada Y,
    3. Koarada S,
    4. Horiuchi T,
    5. Tsukamoto H,
    6. Murai K,
    7. et al.
    Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005;14:385–90.
    OpenUrlCrossRefPubMed
  56. 56.
    1. Yang XY,
    2. Xu DH
    . MDR1(ABCB1) gene polymorphisms associated with steroid induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie 2007;62:930–2.
    OpenUrlPubMed
  57. 57.↵
    1. Yang Y,
    2. Kumar S,
    3. Lim LS,
    4. Silverman ED,
    5. Levy DM
    . Risk factors for symptomatic avascular necrosis in childhood-onset systemic lupus erythematosus. J Rheumatol 2015;42:2304–9.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Petri M
    . Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995;8:137–45.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Fernandes EG,
    2. Guissa VR,
    3. Saviolli C,
    4. Siqueira JT,
    5. Valente M,
    6. da Silva CA
    . Osteonecrosis of the jaw on imaging exams of patients with juvenile systemic lupus erythematosus. Rev Bras Reumatol 2010;50:3–15.
    OpenUrlPubMed
  60. 60.↵
    1. Griffiths ID,
    2. Maini RN,
    3. Scott JT
    . Clinical and radiological features of osteonecrosis in systemic lupus erythematosus. Ann Rheum Dis 1979;38:413–22.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Kunyakham W,
    2. Foocharoen C,
    3. Mahakkanukrauh A,
    4. Suwannaroj S,
    5. Nanagara R
    . Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac J Allergy Immunol 2012;30:152–7.
    OpenUrlPubMed
  62. 62.↵
    1. Li X,
    2. Ren Q,
    3. Chen Z,
    4. Li X,
    5. Wang G
    . Risk factors for avascular necrosis in patients with systemic lupus erythematosus [abstract]. Int J Rheum Dis Suppl 2013;16 Suppl 1:1–48.
    OpenUrl
  63. 63.↵
    1. Tektonidou MG,
    2. Malagari K,
    3. Vlachoyiannopoulos PG,
    4. Kelekis DA,
    5. Moutsopoulos HM
    . Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 2003;48:732–6.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Zheng W,
    2. Wu HH,
    3. Wu X,
    4. Zhao Y,
    5. Zeng XF,
    6. Zhang FC
    . Clinical features of SLE patients with knee osteonecrosis [abstract]. Int J Rheum Dis 2014;68:0238.
    OpenUrl
  65. 65.↵
    1. Zonana-Nacach A,
    2. Barr SG,
    3. Magder LS,
    4. Petri M
    . Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Espinola RG,
    2. Pierangeli SS,
    3. Gharavi AE,
    4. Harris EN
    . Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518–22.
    OpenUrlPubMed
  67. 67.↵
    1. Wallace DJ,
    2. Metzger AL,
    3. Stecher VJ,
    4. Turnbull BA,
    5. Kern PA
    . Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322–6.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Seleznick MJ,
    2. Silveira LH,
    3. Espinoza LR
    . Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol 1991;18:1416–7.
    OpenUrlPubMed
  69. 69.↵
    1. Nevskaya T,
    2. Gamble MP,
    3. Pope JE
    . A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol 2017;35:700–10.
    OpenUrl
  70. 70.↵
    1. Zhu KK,
    2. Xu WD,
    3. Pan HF,
    4. Zhang M,
    5. Ni J,
    6. Ge FY,
    7. et al.
    The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 2014;37:1852–64.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

SYSTEMIC LUPUS ERYTHEMATOSUS
OSTEONECROSIS
METAANALYSIS
REVIEW

Keywords